Product name: Gypenoside XIII
Synonym name: Ginsenoside Mx; Gynosaponin M
Catalogue No.: BP2101
Cas No.: 80325-22-0
Formula: C₄₁H₇₀O₁₂
Mol Weight: 754.999
Botanical Source: Gynostemma pentaphyllum (Thunb.) Makino
Type of Compound: Triterpenoids

Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle

Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.

The product could be supplied from milligrams to grams
Inquire for bulk scale.

For Reference Standard and R&D, Not for Human Use Directly.

HPLC of Gypenoside XIII

Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃

Introduction/Overview

Gypenoside XIII, as one of the important active ingredients in Gynostemma pentaphyllum, has attracted widespread attention in the field of natural product pharmacology in recent years. Jiaogulan is a traditional Chinese medicinal herb, known as the "Southern Ginseng" due to its abundant saponin content. It possesses multiple biological activities and shows significant potential especially in the prevention and treatment of cardiovascular diseases. Gypenosides are a class of structurally diverse triterpene saponin mixtures. Gypenosides XIII, as its monomer component, has become a research hotspot due to its unique structure and multi-target mechanism.

This review focuses on the chemical structure, physicochemical properties, plant origin, and extraction method of gynostemma saponin XIII, delving into its pharmacological activity and mechanism of action. Combining druggability evaluation and pharmacokinetic data, it looks ahead to its clinical application prospects. By systematically reviewing relevant literature, the aim is to provide a theoretical foundation and research direction for drug development of this natural product.

Chemical structure and physicochemical properties

Gynostemma saponin XIII has the molecular formula C42H70O13 and a molecular weight of 754.9990. Its structure belongs to pentacyclic triterpene saponins, with a core of a ginsenoside backbone connected to multiple glycan residues. The compound has a LogP value of 3.5019, showing moderate lipid solubility, which facilitates membrane penetration. The polar surface area (TPSA) is 198.7600, indicating a high number of polar groups, which may affect its water solubility and bioavailability. Experimental measurements showed a water solubility of 0.0112 mg/mL, classifying it as a low-soluble compound.

Gynostemma saponin XIII shows low permeability of the blood-brain barrier, indicating difficulty entering the central nervous system. The hERG channel inhibition test was negative, indicating a low cardiotoxicity risk for this compound. The Ames mutagenic test result was 0.0, indicating no significant mutagenicity and good safety.

From a chemical structure perspective, the polysaccharide chain and triterpene framework of gynostemma saponin XIII provide the basis for its biological activity, but also bring challenges in druggability, such as poor water solubility and low bioavailability.

Plant Origins and Extraction Methods

Gynostemma saponin XIII mainly originates from the plant Gynostemma pentaphyllum, a plant of the Cucurbitaceae family, which is widely distributed in southern China and Southeast Asia. Gynostemma is widely cultivated and studied for its medicinal value, and its whole plant is rich in saponin compounds.

Common methods for extracting gynostemma saponin XIII include solvent extraction, column chromatography separation, and high-performance liquid chromatography (HPLC) purification. Generally, 70%-80% ethanol or methanol is used for crude extraction, followed by separation and purification through silica gel columns or reversed-phase C18 columns. In recent years, the application of ultrasound-assisted extraction and microwave-assisted extraction technologies has improved extraction efficiency and purity.

The purified gynostema saponin XIII was structurally identified using mass spectrometry (MS), nuclear magnetic resonance (NMR), and infrared spectroscopy (IR) to ensure its purity and structural accuracy. Due to the complex composition of gynostemma saponins, optimizing the extraction process is crucial for obtaining high-purity gynostemma saponin XIII.

Pharmacological activity research

Gynostemma saponin XIII, as the monomer component of total gynostemma saponins, exhibits multiple pharmacological activities, especially playing a significant role in cardiovascular protection and anti-tumor fields.

Cardiovascular protective effects

Total gynostemma saponins have been proven to improve lipid metabolism and inhibit atherosclerosis, with gynostemma XIII playing a key role. In vitro and in vivo studies have shown that gynostemma saponin XIII can regulate the expression of genes related to cholesterol metabolism, promote the production of high-density lipoprotein cholesterol (HDL-C), inhibit low-density lipoprotein (LDL) oxidation, and slow down arterial endothelial cell damage. Additionally, its anti-inflammatory effect helps reduce inflammatory responses in blood vessel walls and blocks the progression of atherosclerosis.

Antitumor activity

In recent years, gynostemma saponin XIII has shown potential antitumor activity in tumor models such as lung cancer. By regulating various signaling pathways, it inhibits tumor cell proliferation, induces apoptosis, and suppresses migration and invasion. In vitro experiments show that gynostemma saponin XIII can downregulate the expression of the anti-apoptotic protein BCL2, activate apoptosis-related enzyme systems, and inhibit tumor cell viability.

Additionally, gynostemma saponin XIII regulates inflammatory responses in the tumor microenvironment, reduces the expression of pro-tumor factors such as MMP2 and STAT3, and inhibits tumor angiogenesis and metastasis. Its multi-target action makes it a strong candidate for antitumor drug development.

Other pharmacological effects

Gynostemma saponin XIII also exhibits multiple biological activities, including antioxidant, immunomodulatory, and neuroprotective effects. Its antioxidant effect is achieved by scavenging free radicals and enhancing the activity of endogenous antioxidant enzymes, helping to alleviate pathological damage from oxidative stress-related diseases.

Mechanism of action and molecular targets

The pharmacological mechanism of gynostemma saponin XIII involves multiple signaling pathways and molecular targets, with particular performance in lung cancer treatment. The main targets include:

• BCL2: Gynostemma saponin XIII promotes tumor cell apoptosis by inhibiting BCL2 expression, breaking cell survival signals.
• ABCA1: Regulates cholesterol transport, promotes cholesterol reverse transport, and exerts anti-atherosclerosis effects.
• TLR4: Inhibits TLR4-mediated inflammatory signals, reduces inflammatory responses, and protects vascular endothelium.
• STAT3: Inhibits the STAT3 signaling pathway, blocking tumor cell proliferation and immune escape.
• ESR2: Regulates estrogen receptor β, participating in cell proliferation and differentiation regulation.
• MAPT: Affects microtubule-associated proteins and regulates cytoskeletal stability.
• MMP2: Inhibits matrix metalloproteinase 2, blocking tumor cell migration and invasion.
• PIK3CG: Regulates the PI3K/Akt signaling pathway, affecting cell metabolism and survival.
• RELA: Inhibits the NF-κB signaling pathway, reducing inflammation and tumor progression.
• MAPK1: Regulates cell proliferation and stress response.

Gynostemma saponin XIII achieves its complex biological effects through multi-target and multi-pathway synergistic effects. This multi-target characteristic not only enhances its therapeutic efficacy but also reduces the risk of resistance.

Druggability evaluation and pharmacokinetics

The druggability parameters of gynostemma saponin XIII indicate that it has certain development potential. Although the molecular weight of 754.9990 is relatively large, it falls within the common range for natural product drugs. The LogP was 3.5, indicating moderate lipid solubility and favorable cell membrane penetration. A high TPSA value (198.76) suggests strong polarity, which may limit oral absorption and bioavailability.

Low water solubility (0.0112 mg/mL) is a major challenge for druggability, requiring formulation techniques such as nanocarriers and solid dispersions to improve solubility and stability. The low permeability of the blood-brain barrier limits its application in central nervous system diseases, but it is more suitable for peripheral diseases such as cardiovascular and lung cancer.

In terms of safety, gynostemma saponin XIII does not inhibit hERG channels, reducing the risk of cardiotoxicity. The Ames test was negative, indicating no mutagenicity and relatively high safety.

Pharmacokinetic research is still in its early stages. In vivo, metabolic pathways mainly involve hepatic enzyme systems, possibly metabolizing glycosides through hydrolysis and oxidation reactions. Bioavailability is limited by its water solubility and metabolic rate; further research is needed on its absorption, distribution, metabolism, and excretion (ADME) characteristics in the future to guide clinical dosage formulation design and administration regimens.

Prospects and outlooks for clinical applications

With its multiple pharmacological activities, especially its potential in cardiovascular disease prevention and lung cancer treatment, gynostemma XIII shows broad clinical application prospects. Its anti-atherosclerotic effect provides cardiovascular disease patients with a new natural drug option, especially suitable for long-term conditioning and adjunctive therapy.

In the oncology field, gynostemma saponin XIII, as a multi-target natural product, is expected to be used synergistically with existing chemotherapy drugs to enhance efficacy and reduce side effects. Its immunomodulatory and anti-inflammatory properties also provide auxiliary support for tumor immunotherapy.

Future research should focus on the following aspects:

1. Pharmacokinetic optimization: Improving bioavailability through formulation improvement, overcoming limitations of poor water solubility.
2. In-depth analysis of the mechanism of action: Using modern molecular biology techniques, elucidating its multi-target synergistic network.
3. Preclinical safety and efficacy evaluation: Conduct systematic toxicology and pharmacodynamic studies to ensure clinical application safety.
4. Clinical trial design: Advance early clinical trials to verify efficacy and safety in cardiovascular diseases and lung cancer.
5. Combination drug research: Explore synergistic mechanisms with other drugs to enhance overall treatment effectiveness.

Gynostemma saponin XIII, as a model for natural product drug development, holds significant scientific value and application potential.

Conclusion

In summary, Gynostemma saponin XIII, as an important active ingredient in total gynostemma, demonstrates multi-target and multi-pathway pharmacological activity, especially in cardiovascular disease prevention and lung cancer treatment. Its unique chemical structure and physicochemical properties provide a foundation for drug development, but issues such as poor water solubility and low bioavailability urgently need to be addressed.

In the future, through in-depth mechanistic research, pharmacokinetic optimization, and clinical validation, gynostemma saponin XIII is expected to become an important candidate for novel natural drugs, bringing new hope for the treatment of related diseases. The diversity and complexity of natural products provide abundant resources for modern drug development, and research progress on gynostemma saponin XIII will also drive the development and innovation of natural product pharmacology.